September 23, 2014 12:26 PM ET

Healthcare Equipment and Supplies

Company Overview of Cordis Corporation

Company Overview

Cordis Corporation, through its subsidiaries, develops, manufactures, and distributes drug-eluting stents, catheters, and guide wires for interventional medicine, minimally invasive computer-based imaging, and electrophysiology applications. The company offers a portfolio of access, diagnostic, and interventional medical products for use in cardiovascular, endovascular, and biliary duct (liver) obstructive interventional procedures. Its cardiology products include transradial solutions for radial access procedures; diagnostic products, such as access kits, sheath introducers, diagnostic guide wires, and diagnostic catheters; guiding and PTCA dilatation catheters; and steerable guide wires an...

430 Route 22 East

Bridgewater, NJ 08807

United States

Founded in 1959

3,620 Employees

Phone:

908-541-4100

Fax:

800-997-1122

Key Executives for Cordis Corporation

Vice President of Worldwide Clinical Research & Operations
Chief Scientific Officer and Global Head of Research & Development
Age: 53
Vice President of Regulatory Affairs and Quality Assurance
Age: 66
Vice President of Latin American Operations
Age: 85
Vice President of Corporate Relations and Assistant Secretary
Age: 77
Compensation as of Fiscal Year 2014.

Cordis Corporation Key Developments

Cordis Corporation Launches INCRAFT(R) AAA Stent Graft System for Treatment of Abdominal Aortic Aneurysms (AAA)

Cordis Corporation announced the launch of its INCRAFT(R) AAA Stent Graft System (INCRAFT(R) System), an ultra-low profile device for use during endovascular aneurysm repair (EVAR) for patients suffering from infrarenal abdominal aortic aneurysms (AAA). The INCRAFT(R) System is cleared for use and now available in Europe and Canada. This device is an advancement in the EVAR field and provides a new option for patients and physicians seeking a less invasive treatment approach for AAA. An estimated 24 million people worldwide suffer from AAA, an abnormal enlargement of the large blood vessel (aorta) that supplies blood to the abdomen, pelvis and legs. Left untreated, all aneurysms will eventually rupture and the majority of ruptured aneurysms result in death. The INCRAFT(R) System is intended for the endovascular treatment of patients with infrarenal AAA. The INCRAFT(R) System, which features an ultra-low profile endovascular stent graft system with innovative technology designed for durability, conformability and sealing without the need for polymers, is intended to reinforce the lower part of the aorta to prevent an aneurysm from rupturing. The INCRAFT(R) System is the lowest profile EVAR system now available in Europe and Canada with a 14 French (F) outer diameter, including the integrated sheath, which is equivalent to a 12F catheter sheath introducer profile. Most EVAR stent grafts have a system profile ranging from 16F to 22F in size. This ultra-low profile device is designed for proximal and distal placement accuracy and allows for customization during the procedure to accommodate a wide range of anatomical sizes. This broad anatomical coverage is offered with a minimal number of product codes for easier pre-procedural planning. The INNOVATION Trial is a multicenter, open-label, prospective, non-randomized study designed to assess the safety and performance of the device in the treatment of patients with AAA with investigational sites in Germany and Italy. At two years, results from the study demonstrated the device performed well in patients and showed no incidences of aneurysm enlargement, endoleaks (type I, or III), device or procedure related major adverse events, stent-graft migrations or stent fractures. One patient in the study developed a late graft occlusion unrelated to the device that was caused by shrinkage of the aneurysm. The two-year study results were presented at the 2014 Charing Cross Symposium and subsequently published in the July 2014 online issue of the Journal of Vascular Surgery. The INCRAFT(R) System is currently approved for investigational device use only in the U.S. and Japan and is being studied in a global pivotal clinical study in the U.S. and Japan called the INSPIRATION Trial, which completed enrollment in 2013.

Johnson & Johnson Reportedly Plans To Shed Cordis

Johnson & Johnson (NYSE:JNJ) reportedly intends to dispose of its medical devices unit Cordis Corporation. A potential sale which is currently in its early stages could bring between $1.5 billion and $2 billion. The unit was expected to attract bids from private equity players and rival healthcare companies.

Cordis Corporation Launches SABER(TM) PTA Dilatation Catheter to Complement Portfolio of Peripheral Arterial Disease Treatments

Cordis Corporation announced the launch of its SABER(TM) PTA Dilatation Catheter for the treatment of patients with Peripheral Arterial Disease (PAD). The SABER(TM) Catheter is cleared for use and now available in Europe, the United States and Japan. This new CORDIS(R) product offers outstanding crossability and a comprehensive offering of balloon sizes on the widely-used 0.018" over-the-wire platform. Physicians can now treat a wider range of PAD patients with a single balloon brand. Developed to complement the CORDIS(R) PTA portfolio as a next-generation, high-performance workhorse 0.018" PTA balloon catheter, SABER(TM) Catheter is intended to dilate stenoses in iliac, femoral, ilio-femoral, popliteal, infrapopliteal and renal arteries and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. The device is also indicated for post-dilation of balloon-expandable and self-expanding stents in the peripheral vasculature. SABER(TM) Catheter is available in balloon diameters of 2-10mm and lengths of 20-300mm. SABER(TM) Catheter combines a durable dual layer hydrophilic coating with a low-profile body and new molded tip design to enhance crossability. The catheter has exceptional rated burst pressures of up to 18 atm due to its construction with trusted DURALYN(R) Material.

Similar Private Companies By Industry

Company Name Region
MCA Microvascular United States
Grass Technologies Corporation United States
ScyFIX, LLC United States
Electrochemical Oxygen Concepts Inc. United States
J. Morita USA, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
January 20, 2014
Conor Medsystems, LLC
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cordis Corporation, please visit www.cordis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.